Welcome to The Beckley Foundation and our new website.
We are continuing to curate content throughout the site, if you are looking for something specific that is not featured you may want to check our archived site here.
The Beckley / Imperial Research Programme aims to develop a comprehensive account of how substances such as LSD, psilocybin, and MDMA affect the brain to alter consciousness, and how they produce their potentially therapeutic effects. We use the latest developments in brain imaging technology and analysis methods to measure brain blood flow, brain network connectivity, and neural oscillations (rhythmical activity, or ‘brain waves’) during the psychedelic experience. This understanding greatly adds to the evidence base supporting the therapeutic potential of these substances, while teaching us about consciousness itself. Our studies have resulted in over 20 publications in high-impact scientific journals, and have led to the recent completion of a breakthrough clinical trial, funded by the Medical Research Council, to investigate psilocybin in the treatment of depression.
LSD, compared to placebo, increases the connectivity of the visual areas
David Nutt, together with Amanda Feilding, is Co-Director of the Programme. David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.
Robin Carhart-Harris is the lead investigator of the Beckley / Imperial Research Programme. He has a degree in Psychology, MA in Psychoanalysis, and PhD in the field of Psychopharmacology, and is currently a Research Associate in the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.
Mendel Kaelen was a Beckley / Imperial Research Programme Fellow, and a PhD student in the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London and also a musician. His dissertation project investigates the interaction between LSD and music.
This collaboration was formed in 2005, when Amanda convinced David Nutt – then at the University of Bristol – that they should form a collaborative partnership. She also suggested that Robin Carhart-Harris carry out his PhD under Nutt’s supervision. In 2009, David Nutt moved to Imperial College London, and their collaboration became the Beckley / Imperial Research Programme, with Amanda and David as co-directors and Robin as lead investigator. In 2012, the first results of their brain imaging study with psilocybin were published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) and achieved world-wide publicity. Based on this work, the Programme later received a substantial grant from the Medical Research Council to study the effects of psilocybin in the treatment of depression.
Also in 2012, the Beckley / Imperial Research Programme carried out the first brain imaging study of MDMA (‘Ecstasy’), as part of the Channel 4 programme Drugs Live: The Ecstasy Trial. This was the first detailed study to map the neural underpinnings of MDMA’s effects, and to explain why it is so valuable for psychotherapy.
In 2014, the Programme, at last, launched the first-ever brain imaging study with LSD – a study Amanda has longed to do ever since the 1960s. The results have proven to be as ground-breaking as those of the psilocybin studies. To supplement the funding to complete the study, the Beckley Foundation launched a successful crowdfunding campaign with the website Walacea.
Future Beckley / Imperial studies will investigate the relationship between LSD and creativity, using the ancient Chinese game ‘Go’. Studies comparing the effects of DMT (the main psychoactive ingredient of ayahuasca) to those of psilocybin and LSD are also being planned in order to examine their similarities and differences, and to further understand phenomena of altered consciousness such as ‘seeing with eyes shut’ and the experience of ‘entities.’
Language, Cognition and Neuroscience, 2016
Lancet Psychiatry, 2016
Psychological Medicine, 2016
Human Brain Mapping, 2016
Journal of Psychopharmacology, 2016
Human Brain Mapping, 2016
Proceedings of the National Academy of Sciences of the USA, 2016
Current Biology, 2016
European Neuropsychopharmacology, 2016
Biological psychiatry, 2014
Human Brain Mapping, 2015
Human brain mapping, 2014
Frontiers in human neuroscience, 2014
International Journal of Neuropsychopharmacology, 2014
Current Drug Abuse Reviews, 2014
Journal of The Royal Society Interface, 2014
Frontiers in Human Neuroscience, 2014
Schizophrenia bulletin, 2013
The Journal of Neuroscience, 2013
The British Journal of Psychiatry, 2012
Proceedings of the National Academy of Sciences of the USA, 2012
Journal of Psychopharmacology, 2010
Type of publication